Bluejay Diagnostics (BJDX) EBIT (2020 - 2026)

Bluejay Diagnostics (BJDX) has 7 years of EBIT data on file, last reported at -$1.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 2.64% year-over-year to -$1.9 million; the trailing twelve-month figure through Mar 2026 stood at -$7.0 million (down 5.62% YoY), and the FY2025 full-year result was -$7.0 million, up 3.02% from the prior year.
• EBIT slipped to -$1.9 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$1.4 million in Q3 2024 to a low of -$2.9 million in Q2 2023.
• A 5-year average of -$2.1 million and a median of -$2.0 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT tumbled 786.91% in 2022 and jumped 41.84% in 2024, its largest moves.
• Tracing BJDX's EBIT over 5 years: stood at -$2.5 million in 2022, then rose by 2.73% to -$2.4 million in 2023, then soared by 37.8% to -$1.5 million in 2024, then grew by 1.54% to -$1.5 million in 2025, then plunged by 32.64% to -$1.9 million in 2026.
• Business Quant data shows BJDX's EBIT at -$1.9 million in Q1 2026, -$1.5 million in Q4 2025, and -$1.6 million in Q3 2025.